Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Essential Drug List Expected In June

This article was originally published in PharmAsia News

Executive Summary

At a recent national pharmacist conference in Beijing, high-level executives and experts from China's government organizations such as the Ministry of Health, State FDA and National People's Congress Finance and Economy Committee gathered to discuss the healthcare reform. The spotlight was on the long-awaited essential drug list (PharmAsia News, May 2007, 2009), which authorities indicated would likely be out by the end of June. A large reduction in the number of TCM entries was confirmed. Also, healthcare institutions will need to prescribe essential drugs by percentage of revenue rather than by drug types. Relevant supplementary documents will be issued progressively for the list, including implementation opinions and administration regulations. Analysts believe that in the short term, the essential drug market will be concentrated at grassroots-level and rural medical organizations. (Click here for more - Chinese Language)

You may also be interested in...



China’s Essential Drug System Expected To Consolidate Generic Industry, Promote Innovative R&D

SHANGHAI - China's essential drug system will hasten the consolidation of the generic industry while a measure for drug pricing will encourage innovation, according to a Frost & Sullivan report on the impact of China's healthcare reform, released May 18

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel